183 related articles for article (PubMed ID: 8947826)
1. Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation.
Lindheim SR; Barad DH; Witt B; Ditkoff E; Sauer MV
J Assist Reprod Genet; 1996 Oct; 13(9):745-7. PubMed ID: 8947826
[TBL] [Abstract][Full Text] [Related]
2. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
[TBL] [Abstract][Full Text] [Related]
3. Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization.
Mashiach S; Dor J; Goldenberg M; Shalev J; Levran D; Rudak E; Nebel L; Goldman B; Blankstein J; Ben-Rafael Z
Gynecol Endocrinol; 1989 Jun; 3(2):107-15. PubMed ID: 2816477
[TBL] [Abstract][Full Text] [Related]
4. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression.
Branigan EF; Estes MA
Fertil Steril; 2000 Mar; 73(3):587-90. PubMed ID: 10689017
[TBL] [Abstract][Full Text] [Related]
5. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
[TBL] [Abstract][Full Text] [Related]
7. Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF-ET?
al-Mizyen E; Sabatini L; Lower AM; Wilson CM; al-Shawaf T; Grudzinskas JG
J Assist Reprod Genet; 2000 Mar; 17(3):140-6. PubMed ID: 10911573
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
9. Results of planned in-vitro fertilization programming through the pre-administration of the oestrogen-progesterone combined pill.
Cohen J; Debache C; Solal P; Serkine AM; Achard B; Boujenah A; Pez JP; Paris X; Robert J; Loffredo V
Hum Reprod; 1987 Jan; 2(1):7-9. PubMed ID: 3106405
[TBL] [Abstract][Full Text] [Related]
10. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
11. Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?
Haas J; Zilberberg E; Machtinger R; Kedem A; Hourvitz A; Orvieto R
Gynecol Endocrinol; 2015 Jan; 31(1):79-82. PubMed ID: 25223892
[TBL] [Abstract][Full Text] [Related]
12. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization.
San Roman GA; Surrey ES; Judd HL; Kerin JF
Fertil Steril; 1992 Oct; 58(4):744-9. PubMed ID: 1426320
[TBL] [Abstract][Full Text] [Related]
14. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
Jiang S; Kuang Y
Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
[TBL] [Abstract][Full Text] [Related]
15. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization].
Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490
[TBL] [Abstract][Full Text] [Related]
16. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.
Wei D; Shi Y; Li J; Wang Z; Zhang L; Sun Y; Zhou H; Xu Y; Wu C; Liu L; Wu Q; Zhuang L; Du Y; Li W; Zhang H; Legro RS; Chen ZJ
Hum Reprod; 2017 Feb; 32(2):354-361. PubMed ID: 27999118
[TBL] [Abstract][Full Text] [Related]
17. Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation.
Huang FJ; Chang SY; Tsai MY; Kung FT; Wu JF; Chang HW
J Assist Reprod Genet; 2001 Feb; 18(2):91-6. PubMed ID: 11285987
[TBL] [Abstract][Full Text] [Related]
18. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
[TBL] [Abstract][Full Text] [Related]
19. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
Zhu X; Zhang X; Fu Y
Medicine (Baltimore); 2015 May; 94(21):e909. PubMed ID: 26020402
[TBL] [Abstract][Full Text] [Related]
20. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
